At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
APRE Aprea Therapeutics, Inc.
Trading 11-26 09:39:48 EST
2.97
+0.06
+1.95%
High2.97
Low2.88
Vol1.86K
Open2.88
D1 Closing2.91
Amplitude2.98%
Mkt Cap16.12M
Tradable Cap11.81M
Total Shares5.43M
T/O5.41K
T/O Rate0.05%
Tradable Shares3.98M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Aprea Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
BRIEF-Aprea Therapeutics - Got Into At The Market Offering Agreement, May Offer & Sell Shares Of Common Stock Of Up To $3 Million From Time To Time - SEC Filing
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.